# Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency

> **NCT00056589** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 11 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Congenital FXIII Deficiency

## Interventions

- **DRUG:** catridecacog

## Key facts

- **NCT ID:** NCT00056589
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056589, "Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00056589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*